These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21852468)

  • 21. Fragment-based screening in tandem with phenotypic screening provides novel antiparasitic hits.
    Blaazer AR; Orrling KM; Shanmugham A; Jansen C; Maes L; Edink E; Sterk GJ; Siderius M; England P; Bailey D; de Esch IJ; Leurs R
    J Biomol Screen; 2015 Jan; 20(1):131-40. PubMed ID: 25231971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined use of ascorbic acid and cyanocobalamin in clearance of Trypanosoma cruzi.
    Ghobadifar MA; Kalani N; Gitiforouz M
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):401-2. PubMed ID: 24857404
    [No Abstract]   [Full Text] [Related]  

  • 23. In silico repositioning of approved drugs for rare and neglected diseases.
    Ekins S; Williams AJ; Krasowski MD; Freundlich JS
    Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
    Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
    J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antichagasic activity of komaroviquinone is due to generation of reactive oxygen species catalyzed by Trypanosoma cruzi old yellow enzyme.
    Uchiyama N; Kabututu Z; Kubata BK; Kiuchi F; Ito M; Nakajima-Shimada J; Aoki T; Ohkubo K; Fukuzumi S; Martin SK; Honda G; Urade Y
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5123-6. PubMed ID: 16304182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy of Trypanosoma cruzi infections.
    Brener Z
    Adv Pharmacol Chemother; 1975; 13():1-81. PubMed ID: 812348
    [No Abstract]   [Full Text] [Related]  

  • 27. [The therapeutic effect of allopurinol on American trypanosomiasis (Chagas disease) in CFW mice].
    Castrillón Rivera LE; García Fernández W; Pérez Gutiérrez C
    Salud Publica Mex; 1984; 26(2):146-54. PubMed ID: 6427943
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning.
    Kaiser M; Mäser P; Tadoori LP; Ioset JR; Brun R
    PLoS One; 2015; 10(8):e0135556. PubMed ID: 26270335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular dynamics simulations of peptide inhibitors complexed with Trypanosoma cruzi trypanothione reductase.
    Silva Da Rocha Pita S; Batista PR; Albuquerque MG; Pascutti PG
    Chem Biol Drug Des; 2012 Oct; 80(4):561-71. PubMed ID: 22702225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The chemotherapy of Chagas disease].
    Stoppani AO
    Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The urgent need to develop new drugs and tools for the treatment of Chagas disease.
    Muñoz MJ; Murcia L; Segovia M
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):5-7. PubMed ID: 21171870
    [No Abstract]   [Full Text] [Related]  

  • 33. Isoxazolylnaphthoquinone effects on the growth of Trypanosoma cruzi.
    Amuchástegui PI; Moretti ER; Basso B; Sperandeo N; de Bertorello MM
    Rev Argent Microbiol; 1990; 22(4):199-207. PubMed ID: 2129475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chagas disease: pushing through the pipeline.
    Clayton J
    Nature; 2010 Jun; 465(7301):S12-5. PubMed ID: 20571548
    [No Abstract]   [Full Text] [Related]  

  • 35. Trypanocidal activity of extracts and fractions of Bertholletia excelsa.
    Campos FR; Januário AH; Rosas LV; Nascimento SK; Pereira PS; França SC; Cordeiro MS; Toldo MP; Albuquerque S
    Fitoterapia; 2005 Jan; 76(1):26-9. PubMed ID: 15664458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vouching for access.
    Nat Med; 2016 Jul; 22(7):693. PubMed ID: 27387878
    [No Abstract]   [Full Text] [Related]  

  • 37. In silico tools to study molecular targets of neglected diseases: inhibition of TcSir2rp3, an epigenetic enzyme of Trypanosoma cruzi.
    López-López E; Barrientos-Salcedo C; Prieto-Martínez FD; Medina-Franco JL
    Adv Protein Chem Struct Biol; 2020; 122():203-229. PubMed ID: 32951812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recognizing and meeting the challenge of Chagas disease in the USA.
    Bowling J; Walter EA
    Expert Rev Anti Infect Ther; 2009 Dec; 7(10):1223-34. PubMed ID: 19968514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NADPH Producing Enzymes as Promising Drug Targets for Chagas Disease.
    Cordeiro AT
    Curr Med Chem; 2019; 26(36):6564-6571. PubMed ID: 30306853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi.
    Keenan M; Alexander PW; Chaplin JH; Abbott MJ; Diao H; Wang Z; Best WM; Perez CJ; Cornwall SM; Keatley SK; Thompson RC; Charman SA; White KL; Ryan E; Chen G; Ioset JR; von Geldern TW; Chatelain E
    Future Med Chem; 2013 Oct; 5(15):1733-52. PubMed ID: 24144410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.